Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today announces that by mutual agreement, its Chairman, Dr Alan Kingsman, will leave the Board of Oxford BioMedica at the Company’s forthcoming Annual General Meeting on 5 May 2011. Nick Rodgers, Non-Executive Director, Senior Independent Director and Deputy Chairman, will then become Chairman.
The Company expresses its deep gratitude to Dr Kingsman for his invaluable contribution to the Company over the last 15 years. Dr Kingsman will continue to be a consultant to Oxford BioMedica.
For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer
Tel: +44 (0)1865 783 000
Media Enquiries: Emma Thompson/Amber Bielecka/Katja Toon M:Communications
Tel: +44 (0)20 7920 2342
1. Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene- based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Further information is available at www.oxfordbiomedica.co.uk.
